Edesa Biotech (EDSA) has released an update.
Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple international conferences, highlighting its focus on developing treatments for inflammatory and immune-related diseases. The company is advancing several drug candidates, including therapies for vitiligo, allergic contact dermatitis, and acute respiratory distress syndrome.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
